Legal Reasons and/or Threats
- Immunomodulatory treatment reduces the need for ileocecal resection in Crohn’s disease1/24/2022 0:00
- Predictors of suboptimal medication adherence in IBD patients: A single Australian tertiary centre experience1/24/2022 0:00
- Efficacy of once-daily versus twice-daily mesalazine (PENTASA®): Sub-analysis of the left-sided colitis population in the randomised PODIUM trial1/24/2022 0:00
- Use of immunosuppressants and anti-TNF for inflammatory bowel diseases (IBD) in current practice: Data from a French regional survey1/24/2022 0:00
- Adalimumab therapy in ulcerative colitis patients with previous colectomy1/24/2022 0:00
- Does cognitive behavioural therapy (CBT) improve outcomes in IBD? Feasibility, patient acceptance and preliminary results1/24/2022 0:00
- Osteoporosis prophylaxis in IBD: Still a neglected field?1/24/2022 0:00
- What’s cheapest, intravenous iron sucrose- or intravenous iron carboxymaltose treatment in IBD-patients? It depends on the economic evaluation perspective!1/24/2022 0:00
- Clinical benefit of dietary advice in ulcerative colitis (UC): Results of a pilot study1/24/2022 0:00
- Comparative efficiency of current strategies in the treatment for ulcerative colitis severe relapses1/24/2022 0:00
- Are there gender-related differences in the therapeutic management of patients suffering from inflammatory bowel disease? A subgroup analysis of a prospective multicentre online-based trial1/24/2022 0:00
- Bone mineral density assessment in patients with inflammatory bowel diseases1/24/2022 0:00
- What influences persistence with mesalazine therapy? Results from a large pharmacy database1/24/2022 0:00
- Continuing persistence: United States prescription database results from patients persistent with long-term mesalazine therapy1/24/2022 0:00
- The effect of perianal disease on perceived severity of Crohn’s disease1/24/2022 0:00
- Usefulness of oral beclometasone dipropionate to induce remission in active ulcerative colitis patients: Results from the RECLICU study1/24/2022 0:00
- Ask the doctor about inflammatory bowel disease on the Internet: Experiences after more than one thousand questions1/24/2022 0:00
- Response time of azathioprine in steroid-dependent patients with ulcerative colitis: How much time do we to wait?1/24/2022 0:00
- Smoking in Crohn’s disease: Can we do more?1/24/2022 0:00
- Long-term scheduled therapy with Infliximab in inflammatory bowel disease: Results from a single-centre cohort1/24/2022 0:00
- Time trends in the use of medication and intestinal surgery in a Dutch cohort of patients with Crohn’s disease (1980 2004)1/24/2022 0:00
- Immune response to hepatitis B vaccination in patients with inflammatory bowel disease1/24/2022 0:00
- Appropriateness of treatment for fistulizing Crohn’s disease: Findings from a nationwide inflammatory bowel disease cohort1/24/2022 0:00
- Adalimumab for ulcerative colitis patients previously treated with Infliximab: Short and long-term outcomes1/24/2022 0:00
- Safety of thiopurine therapy in inflammatory bowel disease (IBD): Long-term follow-up study of 3,900 patients1/24/2022 0:00
- Cost effectiveness of ulcerative colitis treatment in Germany: A comparison of Mezavant® and Asacol®1/24/2022 0:00
- Maintenance of mucosal healing in ulcerative colitis patients with once-daily versus twice-daily dosing of mesalazine: An analysis of mucosal healing in the PODIUM trial1/24/2022 0:00
- Efficacy of oral iron treatment in iron deficiency anemia in inflammatory bowel disease patients1/24/2022 0:00
- Preliminary outcomes from an MMX® mesalazine patient experience program in patients with ulcerative colitis1/24/2022 0:00
- Results of a controlled trial on multimodal guideline implementation in inflammatory bowel diseases1/24/2022 0:00
- The safety and efficacy of ciclosporin in the outpatient setting1/24/2022 0:00
- Enterocutaneous fistulas in Crohn’s disease clinical characteristics and response to treatment1/24/2022 0:00
- Azathioprine withdrawal in Crohn’s disease: Never-ending story?1/24/2022 0:00
- Do IBD patients change their treating specialist physicians? If so, does it matter?1/24/2022 0:00
- What is the frequency of 5-ASA administration in colitis within clinical practice?1/24/2022 0:00
- Infliximab maintenance treatment in steroid dependent and immunomodulators resistant ulcerative colitis patients1/24/2022 0:00
- The safety and efficacy of induction and maintenance therapy with infliximab in children with severely active Crohn’s disease1/24/2022 0:00
- Medium term efficacy and safety of adalimumab therapy in patients with Crohn’s disease. National data from Hungary1/24/2022 0:00
- Echovirus parotitis and pancreatitis following infliximab and prednisolone therapy in a patient with ulcerative colitis1/24/2022 0:00
- Pilot experience of granulocyte and monocyte apheresis therapy in moderate/severe ulcerative colitis1/24/2022 0:00
- Percutaneous endoscopic gastrostomy (PEG) in patients with Crohn’s disease1/24/2022 0:00
- Optimal duration of maintenance treatment with azathioprine in patients with inflammatory bowel disease1/24/2022 0:00
- Adverse effects of thiopurines in the treatment of Crohn’s disease1/24/2022 0:00
- Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide and mesalazine enemes in active left-sided ulcerative colitis1/24/2022 0:00
- Adalimumab efficacy in steroid-dependent Crohn’s disease patients1/24/2022 0:00
- Effectiveness and adverse effects of azathioprine in inflammatory bowel disease: 5-year follow-up study1/24/2022 0:00
- Long-term remission with certolizumab pegol in Crohn’s disease: Efficacy over 4 years in patients with no prior TNF-a inhibitor exposure (PRECiSE 3 study)1/24/2022 0:00
- The influence of allogenic mesenchymal stem cells of bone marrow on the remission duration of chronic relapsing and continuously relapsing form of ulcerative colitis1/24/2022 0:00
- Predictors of response and remission to certolizumab pegol in patients with Crohn’s disease: Data from the WELCOME study1/24/2022 0:00
- Fecal calprotectin in assessment of Crohn’s disease activity: Correlation with Harvey-Bradshaw Index, endoscopic and histological findings1/24/2022 0:00